

In the Claims

Please amend the claims as follows. Applicant has included herewith a complete claim set with insertions and deletions indicated by underlining and strikethrough, respectively.

1. (Currently amended) A solid preparation with a coating around ~~the~~ a core containing a ~~gene-related~~ nucleic acid drug for oral administration ~~with that provides~~ that provides releasability of the nucleic acid drug in lower digestive tracts, wherein the coating, ~~does not disintegrating~~ disintegrate in the small intestines, ~~and wherein the coating~~ has a double-coated structure of an inner layer comprising a cationic copolymer and an outer layer comprising an anionic copolymer, wherein the core containing the nucleic acid drug contains a binder as an additive, and the mixed ratio of the nucleic acid drug and the binder is 1:0.2-1:5.
2. (Canceled)
3. (Currently amended) The solid preparation for oral administration according to claim ~~2~~ 1 wherein the core containing the ~~gene-related~~ nucleic acid drug further contains an excipient as an additive, and the mixed ratio of the nucleic acid drug, the binder and the excipient is 1:0.2:0.01-1:5:1.
4. (Currently amended) The solid preparation for oral administration according to claims ~~2~~ 1 or 3 wherein the ~~gene-related~~ nucleic acid drug further contains one or both of a disintegrator and a saccharide as additives.
5. (Canceled)
6. (Currently amended) The solid preparation for oral administration according to claim 4 wherein the mixed ratio of the saccharide contained in the core containing the ~~gene-related~~ nucleic acid drug is in the range of 20-60 wt.%.
7. (Currently amended) The solid preparation for oral administration according to claim 4 wherein the disintegrator contained in the core containing the ~~gene-related~~ nucleic acid drug is in

the range of 2-15 wt.%.

8. (Currently amended) The solid preparation for oral administration according to claim 4 wherein the disintegrator is mixed for the production in the ratio of 1:0.05-1:10 against the content of the ~~gene-related~~ nucleic acid drug.
9. (Currently amended) The solid preparation for oral administration according to claim 3 wherein the excipient contained in the core containing the ~~gene-related~~ nucleic acid drug is in the range of 0.1-15 wt.%.
10. (Currently amended) The solid preparation for oral administration according to claim 1 wherein the ~~gene-related~~ nucleic acid drug contained in the core containing the ~~gene-related~~ nucleic acid drug is in the range of 0.1-50 wt.%.
11. (Currently amended) The solid preparation for oral administration according to claim 2 1 wherein the binder contained in the core containing the ~~gene-related~~ nucleic acid drug is in the range of 5-40 wt.%.
12. (Currently amended) The solid preparation for oral administration according to claim 4 wherein the disintegrators are selected from the group consisting of crospovidone, alpha starch, sodium carboxymethyl starch, carmellose, calcium carmellose, sodium carmellose, agar powder, sodium croscarmellose, crystalline cellulose, low substituted hydroxypropyl cellulose, starch, dextrin, hydroxyethylmethyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone, macrogol and mannitol.
13. (Currently amended) The solid preparation for oral administration according to claim 4 wherein the saccharides are monosaccharides and/or disaccharides ~~such as~~ selected from the group consisting of lactose, fructose, sucrose, glucose xylitol, maltose, mannitol and sorbitol, or polysaccharides and derivatives thereof such as cellulose, crystalline cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, ethyl cellulose, starch, dextrin, dextran, pectin and pullulan.

14. (Currently amended) The solid preparation for oral administration according to claim 3 wherein the excipients are selected from the group consisting of light anhydrous silicic acid, ethyl cellulose, carmellose, agar, magnesium aluminosilicate, calcium silicate, magnesium silicate, cyclodextrin, starch, synthetic aluminum silicate, synthetic hydrotalcite, titanium oxide, zinc oxide, magnesium oxide, alumina magnesium hydroxide, magnesium stearate, calcium stearate, aluminum silicate, talc, crystalline cellulose and lactose.

15. (Currently amended) The solid preparation for oral administration according to claim 1 wherein the ~~gene-related~~ nucleic acid drugs are selected from the group consisting of DNA, ~~or~~ RNA, ~~or modified nucleic acids compounds thereof, or nucleic acids compounds thereof~~ conjugated or bound to a carrier.

16. (Currently amended) The solid preparation for oral administration according to claim 2 ~~1~~ wherein the binders are selected from the group consisting of crystalline cellulose, gum arabic, sodium alginate, ethyl cellulose, agar, carboxyvinyl polymer, carmellose, gelatin, low substituted hydroxypropyl cellulose, starch, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, pectin, polyvinylpyrrolidone, macrogol and methyl cellulose.

17. (Currently amended) The solid preparation for oral administration according to claim 15 wherein the carriers ~~comprising~~ are selected from the group consisting of a cationic polymer, cationic lipid, virus vector and phage.

18. (Currently amended) The solid preparation for oral administration according to claim 1 wherein the ~~gene-related drugs are~~ nucleic acid drug is one or more drugs selected from the group comprising a nucleic acid, oligonucleotide, antisense, triple helix forming oligonucleotide (TFO), ribozyme, ~~decoy~~, plasmid, cosmid, ~~P1 phage~~, YAC (yeast artificial chromosome), ~~chromosome~~, aptamer and phage.